Citadel Advisors’s Standard BioTools LAB Stock Holding History

Citadel Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.2K	Buy	22,000 +3,500	+19%	+$4.24K	﹤0.01%	12669
2025 Q4	$23.7K	Sell	18,500 -27,000	-59%	-$36.3K	﹤0.01%	12299
2025 Q3	$59.1K	Buy	45,500 +10,600	+30%	+$13.9K	﹤0.01%	12110
2025 Q2	$41.9K	Buy	34,900 +28,900	+482%	+$32K	﹤0.01%	11857
2025 Q1	$6.48K	Sell	6,000 -700	-10%	-$983	﹤0.01%	13751
2024 Q4	$11.7K	Sell	6,700 -20,500	-75%	-$38.2K	﹤0.01%	13535
2024 Q3	$52.5K	Buy	27,200 +14,400	+113%	+$28.2K	﹤0.01%	11855
2024 Q2	$22.7K	Sell	12,800 -38,322	-75%	-$93.7K	﹤0.01%	12528
2024 Q1	$139K	Buy	51,122 +47,622	+1,361%	+$115K	﹤0.01%	10883
2023 Q4	$7.74K	Sell	3,500 -6,800	-66%	-$14.5K	﹤0.01%	13270
2023 Q3	$29.9K	Buy	10,300 +7,700	+296%	+$20.1K	﹤0.01%	12274
2023 Q2	$5.02K	Sell	2,600 -1,100	-30%	-$2.17K	﹤0.01%	13541
2023 Q1	$7.21K	Sell	3,700 -13,800	-79%	-$27.3K	﹤0.01%	13745
2022 Q4	$20.5K	Buy	17,500 +6,100	+54%	+$7.51K	﹤0.01%	13131
2022 Q3	$13K	Sell	11,400 -8,200	-42%	-$12.4K	﹤0.01%	12200
2022 Q2	$31K	Buy	19,600 +3,000	+18%	+$7.42K	﹤0.01%	12199
2022 Q1	$60K	Sell	16,600 -17,700	-52%	-$61.1K	﹤0.01%	12678
2021 Q4	$134K	Buy	34,300 +2,800	+9%	+$13.1K	﹤0.01%	12408
2021 Q3	$208K	Sell	31,500 -24,200	-43%	-$159K	﹤0.01%	11910
2021 Q2	$343K	Buy	55,700 +10,800	+24%	+$57.7K	﹤0.01%	10940
2021 Q1	$203K	Buy	44,900 +1,100	+3%	+$6.04K	﹤0.01%	11666
2020 Q4	$263K	Sell	43,800 -35,700	-45%	-$235K	﹤0.01%	9293
2020 Q3	$591K	Buy	79,500 +57,800	+266%	+$399K	﹤0.01%	6990
2020 Q2	$87K	Buy	+21,700	New	+$75.6K	﹤0.01%	9070
2019 Q4	–	Sell	-11,800	Closed	-$55K	–	9451
2019 Q3	$55K	Buy	+11,800	New	+$92.9K	﹤0.01%	8675
2019 Q1	–	Sell	-10,600	Closed	-$91K	–	9613
2018 Q4	$91K	Sell	10,600 -200	-2%	-$1.56K	﹤0.01%	8283
2018 Q3	$81K	Sell	10,800 -12,400	-53%	-$88.2K	﹤0.01%	8655
2018 Q2	$138K	Buy	23,200 +900	+4%	+$5.13K	﹤0.01%	8110
2018 Q1	$130K	Buy	22,300 +1,100	+5%	+$7.22K	﹤0.01%	7611
2017 Q4	$125K	Buy	+21,200	New	+$116K	﹤0.01%	7347
2016 Q3	–	Sell	-10,600	Closed	-$96K	–	7504
2016 Q2	$96K	Sell	10,600 -9,000	-46%	-$84.6K	﹤0.01%	6206
2016 Q1	$158K	Buy	19,600 +14,300	+270%	+$103K	﹤0.01%	5796
2015 Q4	$57K	Sell	5,300 -4,300	-45%	-$42.2K	﹤0.01%	7201
2015 Q3	$78K	Sell	9,600 -4,300	-31%	-$67.7K	﹤0.01%	7197
2015 Q2	$336K	Buy	13,900 +4,700	+51%	+$148K	﹤0.01%	5590
2015 Q1	$387K	Buy	9,200 +3,600	+64%	+$142K	﹤0.01%	5302
2014 Q4	$189K	Sell	5,600 -11,700	-68%	-$331K	﹤0.01%	6037
2014 Q3	$424K	Buy	17,300 +6,800	+65%	+$191K	﹤0.01%	4835
2014 Q2	$309K	Buy	10,500 +9,500	+950%	+$304K	﹤0.01%	5036
2014 Q1	$44K	Buy	+1,000	New	+$44K	﹤0.01%	6860

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Citadel Advisors's LAB Position: Q1 2026 in Review

Citadel Advisors increased its Standard BioTools (LAB) stake by 14% in Q1 2026, buying an estimated $180K and bringing the position to 1,225,310 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #7407.

Citadel Advisors first reported a position in LAB in Q4 2013 and has held it in 40 quarters since. The position peaked at $12.2M in Q1 2019. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Citadel Advisors held 1,225,310 shares of Standard BioTools worth $1.13M as of Q1 2026.
Citadel Advisors bought 148,949 Standard BioTools shares in Q1 2026, an estimated $180K.
Standard BioTools made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7407 holding.
Citadel Advisors first reported a position in Standard BioTools in Q4 2013 and has held it in 40 quarters since.
Citadel Advisors's Standard BioTools position peaked at $12.2M in Q1 2019.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.